Stem Cells Industry | Forecast 2030

Grand View Research’s Stem Cells Industry databook is a collection of market sizing & forecasts insights, market dynamics & trends, opportunity assessment, regulatory & technology framework, pricing intelligence, competitive benchmarking analyses, and macro-environmental analysis studies. Within the purview of the databook, such information is systematically analyzed and provided in the form of summary presentations and detailed outlook reports on individual areas of research. The following data points will be included in the final product offering in five reports and one sector report overview.

The stem cells industry data book is a combination of the market data from five reports namely, the stem cells market, human embryonic stem cells market, induced pluripotent stem cells production market, mesenchymal stem cells market, and cancer stem cells market. The stem cells market was valued at USD 13.26 Billion in 2022 with a CAGR of 11.4% during 2023-2030. The induced pluripotent stem cells production market was valued at USD 1.36 Billion in 2022 with a CAGR of 9.3% during 2023-2030. The human embryonic stem cells market was valued at USD 1.10 Billion in 2022 with a CAGR of 10.6% during 2023-2030. The mesenchymal stem cells market was valued at USD 3.02 Billion in 2022 with a CAGR of 11.4% during 2023-2030. Cancer stem cells market was valued at USD 2.59 Billion in 2022 with a CAGR of 12.1% during 2023-2030.

 

Access the Global Stem Cells Industry Data Book, 2023 to 2030, compiled with details like market sizing information & forecasts, trade data, pricing intelligence, competitive benchmarking, macro-environmental analyses, and regulatory & technological framework studies

 

The stem cell market is anticipated to be driven primarily by the expanding development of precision medicine, growth in the number of cell therapy production facilities, and expansion in the number of clinical trials. Recent developments in tissue engineering and stem cell therapy have the potential to attract attention for the treatment of a number of chronic diseases. Additionally, increasing research activities into the synthesis, storage, and characterization of stem cells as well as rising demand for stem cell banking are anticipated to support the market’s revenue growth.

 

Stem Cells Market Insights

The global stem cells market size was valued at USD 14.80 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 11.43% from 2024 to 2030. The growing development of precision medicine, increase in the number of cell therapy production facilities and rising number of clinical trials are expected to be major driving factors of the market. Recent advances in the stem cells therapeutics and the tissue engineering hold the potential to draw the attention for treatment of several diseases. Furthermore, increasing demand for stem cells banking and rise in research activities pertaining to stem cells production, storage, and characterization are also expected to fuel the revenue growth for the market. Technological improvements in the parent and ancillary market for stem cells usage are some of the other factors that reinforce the expected growth in demand for stem cells over the forecast period.

Order your copy of the Free Sample of “Stem Cells Industry Data Book – Human Embryonic Stem Cells, Induced Pluripotent Stem Cells Production, Mesenchymal Stem Cells and Cancer Stem Cells Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 – 2030” Data Book, published by Grand View Research

 

Human Embryonic Stem Cells Market Insights

The global Human Embryonic Stem Cells market size was valued at USD 494.7 million in 2015. These are the pluripotent cells that possess the ability to get differentiated into all germ layers. Rising demand owing to the increasing incidence of genetic disorders is anticipated to boost growth.

Research carried out in order to utilize them for disease eradication is expected to support projected growth. Controlled differentiation that can be achieved in tissue committed cells through the co-culturing with basic fibroblast growth factor is expected to induce growth.Active involvement of the organizations for developing alternative ways of production of hESCs is anticipated to drive progress. For instance, Science University and Oregon Health are engaged in developing blastocyst staged embryos of around 150 cells in order to provide hESC source.

Active involvement of the organizations for developing alternative ways of production of hESCs is anticipated to drive progress. For instance, Science University and Oregon Health are engaged in developing blastocyst staged embryos of around 150 cells in order to provide hESC source.

© 2024 Crivva. All Rights Reserved.